Efficacy of alitretinoin treatment in patients with pustular form of Psoriasis

Active, not recruiting

Conditions: Palmo-Plantar Pustulosis
MedDRA version: 16.0Level: LLTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 100000004858
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Registration Number: EUCTR2010-022843-39-DE

Lead Sponsor: GlaxoSmithKline R&D Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

1. A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea and a follicle-stimulating hormone concentration of ?40 international units (IU)/L.
• Child-bearing potential with negative pregnancy test as determined by a human
chorionic gonadotropin (hCG) test at screening or prior to dosing and either 1) agrees to use a medically acceptable contraception method for an appropriate
period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point and continue contraception until the end of the study, or 2) has only same-sex partners, when this is her preferred and usual lifestyle.
2. Capable of understanding and willing to provide signed and dated written voluntary
informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed.
3. Male or female aged at least 18 years at time of consent and at time of first dose.
4. Have PPP for at least 6 months, with or without psoriasis lesions on other areas of
the skin.
5. A PPPASI score of at least 8 with involvement of at least 10% of the palms and/or the soles.
6. Refractory to standard topical corticosteroid therapy.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

1. Unable to comply with the requirement of the study.
2. Female subjects who are pregnant or who plan to become pregnant or who are breast feeding.
3. Subjects whose disease is adequately controlled by standard non-medicated therapy (skin moisturizing and protection).
4. Known hypersensitivity to other retinoids or vitamin A derivatives, or to any study medication component, especially soybean oil and partly hydrogenated soybean oil.
5. Treated with any of the following treatments 4 weeks before the start of study treatment:
• systemic drugs: corticosteroids, immunosuppressants, methotrexate
• phototherapy: ultraviolet B light therapy [UVB], psoralen with ultraviolet A
combination therapy [PUVA], Grenz rays, X-rays
6. Treated with biologic treatments within 6 weeks prior to start of study treatment.
7. Abnormal hematology.
8. Treated with any systemic or topical retinoids within 3 months or 1 month,
respectively, before start of study treatment.
9. Treated with high-potency topical corticosteroids within 2 weeks before the start of study treatment.
10. Severe generalized pustular psoriasis.
11. A skin condition of palms and/or soles that interferes with the diagnosis of PPP by
the investigator.
12. Any condition that, in the judgment of the investigator, would put the subject at
unacceptable risk for participation in the study.
13. Hepatic insufficiency, severe renal failure, uncontrolled hypercholesterolemia as characterized by:
• AST/ ALT > 2.5 x upper limit of normal (ULN)
• Creatinine clearance <60 mL/min (calculated, Cockcroft-Gault)
• Fasting triglyceridemia > 1.5 x ULN
• Fasting cholesterol > 1.5 x ULN
• Fasting low-density lipoprotein (LDL) cholesterol > 1.5x ULN
14. Subjects with hypothyroidism as indicated by TSH above ULN and T4 test below LLN or hypervitaminosis A.
15. Subjects with unstable cardiac disease or poorly controlled cardiovascular risk
factors, for example:
• Acute coronary syndrome or coronary revascularization (PCI, CABG) within 3
months before start of study treatment
• Poorly controlled diabetes mellitus (HbA1c > 8.5%)
16. Systolic blood pressure =160 mm Hg and/or diastolic blood pressure =100 mm Hg at
the screening examination.
17. Subjects receiving drugs with a potential for drug-drug interaction, such as systemic tetracyclines, ketoconazole, or St. John’s Wort within 1 Week, or receiving systemic itraconazole within 2 Weeks, before start of study treatment.
18. Subjects included in the study of an investigational drug within 2 months before start of study treatment (3 months for biologics).
19. Subjects with a score of 20 or more on CES-D, or with active major psychiatric
disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar
Disorder [I or II], or schizophrenia).
20. Subjects who score a 4 or 5 during the previous 30 days on the CSSRS at Screening or Baseline.
21. Subjects who have made a suicide attempt within the 6 months preceding the
Screening or Baseline visits.